Meeting
2021 ASCO Annual Meeting
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.
Authors
Jian Zhang
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Jian Zhang , Yanchun Meng , Biyun Wang , Leiping Wang , Jun Cao , Zhonghua Tao , Ting Li , Wenqing Yao , Xichun Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT03772353
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1035)
DOI
10.1200/JCO.2021.39.15_suppl.1035
Abstract #
1035
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab ﴾HR+ with or without letrozole﴿ in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer.
First Author: Patricia Villagrasa
Poster
2015 ASCO Annual Meeting
PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.
First Author: Patricia Villagrasa
Poster
2023 ASCO Annual Meeting
Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01).
First Author: Min Yan
Poster
2023 ASCO Annual Meeting
Racial disparities in utilization of first line targeted therapies for metastatic breast cancer.
First Author: Yehoda M. Martei